Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
from some of the nation’s most trusted and well-connected journalists
hosted by STAT+, plus early access and discounts to can’t-miss industry gatherings
delivered to your inbox with the latest market-moving news and insights
that help you stay up to date with the latest research and developments
on the technologies, personalities, power brokers, and political forces driving changes in life science
plus early access and discounts to industry gatherings
delivered straight to your inbox with the latest industry news
that help you stay up to date with industry research and developments
By Dec. 2, 2022
A Somerville startup and an academic lab in Seattle say they have developed a way to use artificial intelligence to design proteins that don’t exist in nature.
Proteins help people move, digest food, and fight infections — to name a few of their numerous functions. They’re also the basis of a nearly $300 billion drug industry for treating cancer, immune diseases, and other conditions. Most of these therapies are only slightly altered versions of natural proteins. And for some scientists, nature is too limiting.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Artificial Intelligence
biotechnology
This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need
Leave a Reply
You must be logged in to post a comment.